Aprea Therapeutics CEO to Present at Biotechnology Conferences

DOYLESTOWN, Pa., Oct. 05, 2026 /CourierPR/ -- Aprea Therapeutics, a clinical-stage precision medicine oncology company, is set to participate in two major conferences in October. Oren Gilad, PhD, the President and CEO of Aprea, will present at the 2026 Maxim Growth Summit, which is scheduled to take place from October 12 to 14 in New York City. Additionally, Gilad will also be present at the Regional Biotechnology Conference, which will be held on October 15 in Doylestown, Pennsylvania.

At the Maxim Growth Summit, Gilad will participate in a fireside chat that will be available on demand for registered attendees. This event is part of a broader series of conferences organized by Maxim Group, a financial services firm that provides research, capital markets, and investment banking services to the biotechnology and healthcare sectors.

The Regional Biotechnology Conference, organized by the Pennsylvania Biotechnology Center, will offer attendees a comprehensive agenda that covers the latest advancements and challenges in the biotechnology industry. Aprea Therapeutics, with its focus on developing targeted therapies for biomarker-defined cancers, is expected to contribute valuable insights at both events.

Aprea’s lead programs, APR-1051 and ATRN-119, are at the forefront of its research and development efforts. APR-1051 is an oral, small-molecule inhibitor of WEE1 kinase, while ATRN-119 is a small molecule ATR inhibitor. Both compounds are in clinical development for solid tumor indications, aiming to exploit vulnerabilities in cancer cells to minimize toxicity and enhance treatment efficacy.

During the conferences, Gilad will likely discuss the company’s progress and future plans, including the potential applications of its technology across various cancer types such as ovarian, colorectal, prostate, and breast cancers. Attendees can expect to gain a deeper understanding of Aprea’s innovative approach to cancer treatment and its potential impact on the broader oncology landscape.

The company’s participation in these high-profile events underscores its commitment to advancing precision medicine and its dedication to improving patient outcomes through targeted therapies. As Aprea continues to make strides in its clinical development, the insights shared at these conferences will be crucial for both the company and the broader biotechnology community.